European Commission refocuses efforts to emphasise bio-economy
This article was originally published in Clinica
Executive Summary
In a mid-term review of the Strategy on Life Sciences and Biotechnology 2002-10, presented by European Commission president Barroso and commissioners Verheugen and Potocnik, a refocus has been proposed to promote a competitive and sustainable European knowledge-based bio-economy. With the recognition that emerging medical technologies are among the sectors that need to benefit from the strategy, the European Commission wants to put a special focus on innovation, research, market development and the debate with society on ethical issues in the field of biotechnology. The Commission recognises that despite many successful European biotech start-ups, EU biotech companies tend to grow slowly and depend on external finance for their research and development.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.